PA
RAPP

Profund Advisors’s Rapport Therapeutics RAPP Stock Holding History

Profund Advisors’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$265K Buy
+6,358
New +$234K 0.01% 887
2026
Q1 		– Sell
-8,880
Closed -$269K – 1313
2025
Q4 		$269K Buy
+8,880
New +$246K 0.01% 954

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Profund Advisors's RAPP Position: Q2 2026 in Review

Profund Advisors opened a new position in Rapport Therapeutics (RAPP) in Q2 2026: 6,358 shares worth $265K. The stake represents 0.01% of the portfolio and ranks #887 among its holdings. This is a return to the name: Profund Advisors previously reported a position in RAPP as recently as Q4 2025.

Profund Advisors first reported a position in RAPP in Q4 2025 and has held it in 2 quarters since. The position peaked at $269K in Q4 2025. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Profund Advisors held 6,358 shares of Rapport Therapeutics worth $265K as of Q2 2026.
  • Rapport Therapeutics was a new Profund Advisors position in Q2 2026.
  • Rapport Therapeutics made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #887 holding.
  • Profund Advisors first reported a position in Rapport Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Profund Advisors's Rapport Therapeutics position peaked at $269K in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.